Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Receivables - Other (2020 - 2025)

Historic Receivables - Other for Kymera Therapeutics (KYMR) over the last 6 years, with Q1 2025 value amounting to $20.0 million.

  • Kymera Therapeutics' Receivables - Other rose 88522.17% to $20.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $20.0 million, marking a year-over-year increase of 88522.17%. This contributed to the annual value of $900000.0 for FY2024, which is 7607.66% down from last year.
  • Kymera Therapeutics' Receivables - Other amounted to $20.0 million in Q1 2025, which was up 88522.17% from $947000.0 recorded in Q4 2024.
  • Over the past 5 years, Kymera Therapeutics' Receivables - Other peaked at $20.0 million during Q1 2025, and registered a low of $100000.0 during Q4 2021.
  • Over the past 5 years, Kymera Therapeutics' median Receivables - Other value was $2.0 million (recorded in 2024), while the average stood at $3.1 million.
  • Per our database at Business Quant, Kymera Therapeutics' Receivables - Other tumbled by 8831.78% in 2021 and then surged by 243700.0% in 2022.
  • Over the past 5 years, Kymera Therapeutics' Receivables - Other (Quarter) stood at $100000.0 in 2021, then surged by 2437.0% to $2.5 million in 2022, then surged by 48.29% to $3.8 million in 2023, then tumbled by 74.83% to $947000.0 in 2024, then surged by 2011.93% to $20.0 million in 2025.
  • Its Receivables - Other stands at $20.0 million for Q1 2025, versus $947000.0 for Q4 2024 and $1.3 million for Q3 2024.